60岁及以上成人接种呼吸道合胞病毒疫苗的成本效果
研究采用决策分析模型评估60岁及以上成人接种呼吸道合胞病毒(RSV)疫苗的成本效果,时间跨度两年,数据来自已发表文献、FDA文件、流行病学数据库和制造商数据。结果显示每挽救一个质量调整生命年(QALY)的社会成本随接种年龄增长而降低,60-<65岁组GSK疫苗为385,829美元、辉瑞疫苗为331,486美元,≥65岁组分别为162,138美元和146,543美元。作者认为RSV疫苗接种可能具有成本效果,尤其在高龄人群中。
要点
- 60岁及以上成人接种RSV疫苗每挽救一个QALY的社会成本因年龄和产品而异。
- ≥65岁组GSK疫苗162,138美元、辉瑞疫苗146,543美元。
- 60-<65岁组GSK疫苗385,829美元、辉瑞疫苗331,486美元。
核心结论
- 60岁及以上成人接种RSV疫苗可能具有成本效果,尤其在高龄人群中。
- 降低疫苗采购成本和持续超过两个RSV季节的效力可使RSV疫苗接种对更广泛目标人群更具成本效果。
研究设计与样本
- 采用决策分析模型评估60岁及以上成人接种RSV疫苗的成本效果,时间跨度为两年。
- 数据来源包括已发表文献、FDA文件、流行病学数据库和制造商数据。
- 追踪RSV相关的门诊、急诊、住院医疗服务利用、RSV归因死亡、损失的质量调整生命年(QALYs)和社会成本。
主要发现
- 每挽救一个QALY的社会成本:≥60岁成人GSK疫苗196,842美元、辉瑞疫苗176,557美元。
- 每挽救一个QALY的社会成本:≥65岁成人GSK疫苗162,138美元、辉瑞疫苗146,543美元。
- 每挽救一个QALY的社会成本:60-<65岁成人GSK疫苗385,829美元、辉瑞疫苗331,486美元。
- 疫苗效力、RSV住院发生率和疫苗成本对每QALY成本影响最大。
- 每挽救一个QALY的成本随接种年龄增长而降低。
临床怎么用
- 2023年6月,ACIP建议60岁及以上成人可接种单剂RSV疫苗,采用共享临床决策。
局限性
- 长期效力等输入参数存在不确定性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Respiratory syncytial virus (RSV) causes substantial morbidity and mortality in older adults. In May 2023, two subunit RSV vaccines (Arexvy [GSK] and Abrysvo [Pfizer]) received approval from the U.S. Food and Drug Administration (FDA). In June 2023, ACIP recommended that adults aged ≥60 years may receive a single dose of RSV vaccine, using shared clinical decision-making. In support of development of this policy, our objective was to assess the cost-effectiveness of RSV vaccination in the general population in this age group. We used a decision-analytical model of RSV over a two-year timeframe using data from published literature, FDA documents, epidemiological databases, and manufacturer data. We tracked RSV-associated outpatient, emergency department, inpatient healthcare utilization, RSV-attributable deaths, quality-adjusted life-years lost (QALYs), and societal costs. The societal cost per QALY saved from RSV vaccination depended on age group and product: adults aged ≥60 years, $196,842 for GSK's vaccine and $176,557 for Pfizer's vaccine; adults ≥65 years, $162,138 for GSK and $146,543 for Pfizer; adults 60- <65 years, $385,829 for GSK and $331,486 for Pfizer. Vaccine efficacy, incidence of RSV hospitalization, and vaccine cost had the greatest influence on cost per QALY. Cost per QALY saved decreased as the age of those vaccinated increased. Inputs such as long-term efficacy are uncertain. RSV vaccination in adults aged ≥60 years may be cost-effective, particularly in those of more advanced age. Lower vaccine acquisition costs and persistent efficacy beyond two RSV seasons would render RSV vaccination more cost-effective for a broader target population. PRIMARY FUNDING SOURCE: US Centers for Disease Control and Prevention.
引用
- Hutton DW, Prosser LA, Rose AM, et al. Cost-effectiveness of vaccinating adults aged 60 years and older against respiratory syncytial virus. Vaccine. 2024. PMID: 39241353. doi:10.1016/j.vaccine.2024.126294
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。